A pivotal phase 3 trial investigating a combination of anti-PD-1 therapy Keytruda and Pfizer’s tyrosine kinase inhibitor Inlyta has shown a significant benefit on both
Novel immunotherapies, notably the immune checkpoint inhibitors, have been shown to be efficacious in patients with advanced renal cell carcinoma (RCC), but
Kidney Cancer Journal Volume 16, Number 4
Kidney Cancer Journal Volume 16, Number 3
Numerous studies have taken aim at what still appears to be a moving target—optimal use of adjuvant therapy. The volume of literature on this treatment setting has
Kidney Cancer Journal Volume 16, Number 3
Tyrosine kinase inhibitors (TKI) directed against the Vascular Endothelial Growth Factor (VEGFR) were unquestionably the gold standard for front-line therapy in
Kidney Cancer Journal Volume 16, Number 3
Clinical trials investigating combinations of antibodies against the immune checkpoints PD-1 or PD-L1 plus targeted therapies against VEGF/VEGFR have shown
Kidney Cancer Journal Volume 16, Number 3
Positive top-line results have been announced from the pivotal Phase III JAVELIN Renal 101 study evaluating bavencio® (avelumab) in combination with inlyta® (axitinib), compared with
Kidney Cancer Journal Volume 16, Number 3
Cytoreductive nephrectomy has been the standard of care in metastatic renal-cell carcinoma for 20 years, supported by randomized trials and large, retrospective studies. However,
Kidney Cancer Journal Volume 16, Number 3
This spring, we launched a new papillary patient community that now has about 120 members and continues to grow. (For what it’s worth, we also have a large chromophobe community and
Kidney Cancer Journal Volume 16, Number 3
Kidney Cancer Journal Volume 16, Number 3